Site-specific controlled-release nanoparticles for immune reprogramming via dual metabolic inhibition against triple-negative breast cancer

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

She, Wenyan;Li, Haimei;Wang, Zichen;Liu, Tingting;Zhao, Dongli;...

通讯作者：

Liu, Yujiao;Liu, Y

作者机构：

[She, Wenyan; Wang, Zichen; Liu, Yi; Liu, Yujiao; Li, Haimei] Wuhan Univ, Coll Chem & Mol Sci, Wuhan 430072, Peoples R China.

[Liu, Tingting; Guo, Zhibin; Liu, YJ; Liu, Yi; Liu, Yujiao] Tiangong Univ, Sch Chem, State Key Lab Separat Membranes & Membrane Proc, Tianjin 300387, Peoples R China.

[Liu, Tingting; Guo, Zhibin; Liu, Yi; Liu, Yujiao] Tiangong Univ, Sch Mat Sci & Engn, Tianjin 300387, Peoples R China.

[Zhao, Dongli] Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.

[Liu, Yi] Wuhan Polytech Univ, Sch Chem & Environm Engn, Wuhan 430023, Peoples R China.

通讯机构：

[Liu, YJ; Liu, Y ] T

Tiangong Univ, Sch Chem, State Key Lab Separat Membranes & Membrane Proc, Tianjin 300387, Peoples R China.

Wuhan Univ, Coll Chem & Mol Sci, Wuhan 430072, Peoples R China.

语种：

英文

关键词：

CRISPR/Cas9;Controlled-release;Immunotherapy;Metabolic therapy;Theranostic;Triple-negative breast cancer (TNBC)

期刊：

Journal of Controlled Release

ISSN：

0168-3659

年：

2024

卷：

366

页码：

204-220

DOI：

10.1016/j.jconrel.2023.12.022

基金类别：

Tianjin [21JCQNJC01470]; Science and Technology Plans of Tianjin [22ZYJDSS00070]; Core Facility of Wuhan University and Large-scale Instrument and Equipment Sharing Platform of the College of Life Sciences of Wuhan University

机构署名：

本校为其他机构

院系归属：

化学与环境工程学院

摘要：

Metabolic heterogeneity and the tumor immunosuppressive microenvironment (TIME) of triple-negative breast cancer (TNBC) hinder therapeutic effectiveness. Although emerging metabolic therapy and immunotherapy show promise, they are limited by off-target effects and immune escape. Here, a redox-activatable, sequentially-releasing nanoparticle (AMANC@M) for tumor-targeted delivery of anticancer agents and CRISPR/Cas9 has been developed. AMANC@M can reverse the TIME through dual metabolic inhibition, thereby enhancing TNBC therapy. AMANC@M demonstrates excellent biosafety and targets tumors precis...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Site-specific controlled-release nanoparticles for immune reprogramming via dual metabolic inhibition against triple-negative breast cancer

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问